DiscoverOncLive® On AirS14 Ep16: Establishing the Rationale for ADC and ICI Combinations in TNBC
S14 Ep16: Establishing the Rationale for ADC and ICI Combinations in TNBC

S14 Ep16: Establishing the Rationale for ADC and ICI Combinations in TNBC

Update: 2025-09-16
Share

Description

In this podcast, experts Virginia Kaklamani, MD, DSc, and Tiffany A. Traina, MD, FASCO, discuss the rationale for and data to support combining TROP2-targeting antibody-drug conjugates (ADCs) with immune checkpoint inhibitors (ICIs) to treat triple-negative breast cancer (TNBC).
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

S14 Ep16: Establishing the Rationale for ADC and ICI Combinations in TNBC

S14 Ep16: Establishing the Rationale for ADC and ICI Combinations in TNBC

OncLive® On Air